Clinical trials: Hair Diseases
Alopecia
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
The purpose of this study is to evaluate hairstyling techniques aimed at increasing efficacy of scalp cooling in the prevention of chemotherapy-induced alopecia, determine scalp cooling effect on persistent chemotherapy-induced…
- Trial name
- NCT05213936
- Testing
- Scalp cooling with hairstyle, Scalp cooling with conditioner and water emulsion
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Montefiore Medical Center
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Coronary Artery Disease, Chest Pain
Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells
Purpose 1. To investigate the effects of cardiac imaging radiation on the induction of DNA double-strand breaks by enumerating gamma-H2AX foci in blood lymphocytes and plucked hair follicle cells. 2.
- Trial name
- NCT02617888
- Testing
- CCTA ~ BREAST SHIELDS
- Volunteers
- 228 people
- Sponsor
- Walter Reed National Military Medical Center
Polycystic Ovary Syndrome, PCOS
Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)
The purpose of this research study is to see if there are differences between African-American and Caucasian girls with Polycystic Ovary Syndrome (PCOS) in how their bodies respond to a type of sugar, called glucose, the body's…
- Trial name
- NCT02052479
- Testing
- Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Alopecia Areata (AA)
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata.
- Trial name
- ARISE (NCT06826196)
- Testing
- ALD-102 Solution
- Where
- 7 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Aldena Therapeutics
Alopecia Areata, Alopecia Areata(AA)
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata
The goal of this observational study is to learn about microvascular changes and hair follicle activity in patients with alopecia areata.
- Conditions
- Alopecia Areata, Alopecia Areata(AA), Alopecia Areata (AA)
- Trial name
- NCT07499713
- Testing
- Microvascular Imaging, Biochemical Biomarker Analysis, Trichoscopic Imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Hair Thinning
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using XVIE solution applied on the scalp of women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07221773
- Testing
- XVIE
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Hair Thinning
Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning.
- Trial name
- NCT06362941
- Testing
- Nutrafol Women's Hair Growth Supplemnt, Nutrafol Women's Balance Hair Growth Supplement, Nutrafol Women's Vegan Hair Growth Supplement
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Wellness Inc.
Hair Problems
Hair Repigmentation During Cerebrolysin Therapy
Open-label histological study of scalp biopsies from patients undergoing treatment with Cerebrolysin as therapy for cerebrovascular disease.
- Trial name
- NCT05288465
- Testing
- Cerebrolysin
- Where
- Mexico
- Volunteers
- 5 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Diabetes Mellitus, Sport Injury
Cryopreserved Hair Follicles for Disease and Cell Replacement
To explore the application of cells expanded from plucked hair follicles after collection, transport, and cryopreservation, in disease modeling and cell-based therapies.
- Conditions
- Diabetes Mellitus, Sport Injury, Injury Traumatic
- Trial name
- NCT06764719
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Acorn Biolabs Inc.
Alopecia Areata
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03137381
- Testing
- CTP-543
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Concert Pharmaceuticals
Alopecia Areata
Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata
The goal of this study is to evaluate the efficacy and safety of combined CO2 fractional laser with Bimatoprost 0.03% as novel treatment of alopecia areata.
- Trial name
- NCT05600673
- Testing
- Bimatoprost 0.03% solution, CO2 fractional laser
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ahmed Hassan Nouh MD
Alopecia, Androgenetic
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
- Trial name
- NCT05802173
- Testing
- TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Technoderma Medicines Inc.
Healthy, Active Non-segmental Vitiligo
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and…
- Conditions
- Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
- Trial name
- NCT07554222
- Testing
- Baricitinib tablets, IBI3013
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
Androgenetic Alopecia
Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
This study evaluated the efficacy and safety of two concentrations of CosmeRNA-ARI Anti Hair Loss Tonic in adults with androgenetic alopecia.
- Trial name
- NCT07898566
- Testing
- Low-Concentration CosmeRNA-ARI Anti Hair Loss Tonic, High-Concentration CosmeRNA-ARI Anti Hair Loss Tonic, Vehicle Control Tonic Without CosmeRNA-AR
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- BIONEER Corporation
Female Pattern Baldness, Hair Loss
ENERGI-F701 for Female Hair Loss Treatment
The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.
- Conditions
- Female Pattern Baldness, Hair Loss, Alopecia
- Trial name
- NCT03351322
- Testing
- ENERGI-F701, Regaine
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Androgenetic Alopecia
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
Androgenetic alopecia is a common condition affects both genders. Patients of androgenetic alopecia following inclusion criteria will be enrolled after ethical approval and informed consent.
- Trial name
- NCT06239207
- Testing
- Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%), Platelet Rich Plasma
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Services Hospital, Lahore
Alopecia Areata
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In the disease, the immune system mistakenly destroys the hair follicle, causing hair to fall out.
- Trial name
- NCT01950780
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University